^
Association details:
| Biomarker: | NPM1 mutation + DNMT3A mutation + KMT2D mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | ziftomenib (KO-539) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
Published date:
12/05/2020
Excerpt:
Kura Oncology, Inc....announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial...An NPM1 mutant patient with DNMT3A and KMT2D co-mutations achieved a complete remission (CR) with no measurable residual disease...
